Patients Report Positive Outcomes for Nonsurgical Treatment of Thumb OA
By Lori Solomon HealthDay Reporter
THURSDAY, Nov. 30, 2023 -- At five years, patients report positive outcomes for nonsurgical treatment of thumb carpometacarpal (CMC-1) osteoarthritis (OA), according to a study published online Oct. 30 in the Journal of Bone & Joint Surgery.
Lisa M. J. Esteban Lopez, from Erasmus Medical Center in Rotterdam, Netherlands, and colleagues investigated patient-reported pain and limitations in activities of daily living (ADL) at a median 6.6 years following nonsurgical treatment (i.e., exercise therapy and use of an orthosis) for CMC-1 OA. The analysis included 217 survey respondents.
The researchers found that at a median 6.6 years, the score on the Michigan Hand Outcomes Questionnaire (MHQ) pain subscale did not differ significantly from that seen at 12 months. There was improvement in MHQ ADL scores of 4.4 points versus that seen at 12 months, but this finding was not clinically relevant. At five or more years, 5 percent of the patients rated their satisfaction as "poor," 14 percent as "moderate," 26 percent as "fair," 39 percent as "good," and 16 percent as "excellent." For the EuroQol-5 Dimensions-5 Levels index, the median score was 0.852 (range, 0.135 to 1). Twenty-two percent of patients converted to surgery at a median follow-up of seven years.
“Our findings support nonsurgical treatment as the first treatment choice and suggest that treatment effects are sustainable," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-12-01 02:34
Read more
- Obesity Could Cause 40% of Hormone-Positive Breast Cancers in Older Women
- Medical Financial Hardships Shared in Cancer-Linked Crowdfunding Stories
- Too Many Meds: 'Polypharmacy' Can Really Harm Alzheimer's Patients
- Botox Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
- 'Dawson's Creek' Star James Van Der Beek Has Colon Cancer
- New Combo Drug Therapy Halves Death Risk From Advanced Hodgkin Lymphoma
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions